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Abstract
Background: This study aimed to investigate the associations between metabolic syndrome (Mets) and
adiponectin concentrations in Iranian adolescents.
Methods: This study was conducted as a sub-study of a national school- based surveillance program in 10–18
year- old students from 27 provinces in Iran. Plasma adiponectin was measured in 180 randomly selected
participants. Metabolic syndrome (Mets) was defined based on the Adult Treatment Panel III (ATP- III) criteria
modified for the pediatric age group. Multiple logistic regression analyses were used to evaluate the association
between adiponectin and cardiometabolic risk factors.
Results: The median of adiponectin concentrations was significantly lower among participants with Mets [2.95 μg/ml
(interquartile range 2.72–3.30)] compared with subjects without Mets [4.55 μg/ml (interquartile range 3.02–5.75)].
Adiponectin showed significant negative association with higher number of Mets components (P- trend < 0.05). Significant
correlations were observed between adiponectin concentrations and metabolic parameters, except blood pressure.
Significant inverse association existed between adiponectin levels and presence of Mets (OR, 0.21; 95%CI: 0.10–0.45;
p< 0.001). In multivariate models, this association remained significant after adjustment for other risk factors (OR, 0.18;
95%CI: 0.07–0.47; p< 0.001.
Conclusions: Adiponectinhas inverse association with cardiometabolic parameters in Iranian adolescents, and it is a
determinant of Mets independent of other risk factors. These findings can be used in comparison with other ethnic
groups. Further longitudinal studies are necessary to assess the clinical impact of such inverse association.
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Background
Metabolic syndrome (Mets) is a cluster of cardiometabolic
risk factors including abdominal obesity, dyslipidemia,
hyperglycemia, and hypertension [1]. A growing body of
evidence has shown that Mets increases cardiovascular
disease (CVD) and all- cause mortality by 1.5–2 folds [2].
Mets is not limited to adults and exists in the
pediatric age group [3], with higher prevalence in the
in the Middle East than in Western countries [4].The
increasing prevalence of the Mets and associated mor-
bidities represents an important health problem world
wide [5].
A number of obesity- related peptide hormones have
been identified to play a role in the pathogenesis of Mets
[6]. Adipokines, as adiponectin, are secreted by adipose
tissue, which are associated with energy regulation, as
well as glucose and lipid metabolism. Adiponectin has
anti- inflammatory and anti- atherogenic effects and reg-
ulates metabolic homeostasis and vasodilatation, then it
increases insulin sensitivity [7, 8]. Studies suggest that
cardiometabolic risk factors as well as obesity- related
disorders are mediated through adipokines associated
with obesity [9, 10].
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Studies conducted in pediatric populations have docu-
mented that plasma adiponectin concentrations have an
inverse correlation with body mass index (BMI), fasting in-
sulin [11, 12], and seem to be associated with a range of
Mets’ components [13]. These findings suggest an etiologic
role for low adiponectin levels in the pathophysiology of
Mets [14]. Moreover, some studies have suggested that the
associations between adiponectin and vascular risk factors
vary across race and ethnic groups. Thus, it is necessary to
obtain more data in diverse populations.
The aim of our study is to evaluate the association
between adiponectin levels and cardiomatabolic risk
factors in a representative sample of Iranian children
and adolescents.
Methods
We have previously described the method of the main
study in detail [15]. Here we present it in brief and focus
on the current sub-study.
The study sample was obtained as part of the third sur-
vey of a national surveillance program entitled “Childhood
and Adolescents of Surveillance and PreventIon of Adult
Noncommunicabledisease’ (CASPIAN- III) study. Overall
5088 students, aged 10–18 years, were selected through
multistage random cluster sampling from urban and rural
areas of 27 provinces in Iran. After a complete explanation
of the study objectives and protocols for the students and
their parents, written informed consent and verbal assent
were obtained from parents and students, respectively.
Clinical and biochemical measurements
Trained research assistants conducted the examinations,
including measurements of anthropometric indexes and
blood pressure (BP) under standard protocols by using
calibrated instruments [15].
Venous blood samples were drawn from all study par-
ticipants after 12 h of overnight fasting and delivered to
the laboratory on the day of blood collection. Fasting
blood glucose (FBG), total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), and triglycerides (TG)
were measured enzymatically by auto-analyzers. HDL-C
was determined after dextran sulfate-magnesium chlor-
ide precipitation of non-HDL-C. According to the Frie-
dewald equation, low-density lipoprotein cholesterol l
(LDL-C) was calculated in serum samples with TG
≤400 mg/dl. For the current sub-study, adiponectin was
measured with the enzyme- linked immunosorbent
assay (ELISA) kit (Abcam, USA) in 180 randomly se-
lected sera. Intra and inter-assay CVs were 10 and 12 %
for adiponectin, respectively.
Criteria for mets
Subjects were classified as having Mets if they had at
least three of the following criteria according to Adult
Treatment Panel III (ATP III) criteria modified for the
pediatric age group.
TG concentration of 150 mg/dL or greater; HDL-C
concentration of40 mg/dL or less; FBG concentration of
100 mg/dL or greater; abdominal obesity: if waist to
height ratio more than 0.5; and either systolic or dia-
stolic BP (SBP, DBP) greater than the 90th percentile for
age, sex, and height [16].
Statistical analysis
Normal distribution of continuous variables was assessed
using Kolmogorov- Smirnov test. Means ± standard devi-
ation (SD) or median (interquartile range) was used to
express standard descriptive statistics. Categorical vari-
ables are expressed as percentages.
Differences between groups were investigated by T-test,
and Mann- Whitney test in continuous variables with
normal distribution and without normal distribution, re-
spectively. Percentages of the categorized variables were
compared using the Pearson Chi-square test. Spearman
correlation was applied to determine the correlation be-
tween adiponectin and cardiometabolic parameters. Lo-
gistic regression analyses were used to evaluate the
association between the Mets and adiponectin concen-
trations and other cardio-metabolic risk factors in each
model by adjustment for possible confounders. All statis-
tical analyses were performed by the SPSS statistical pack-
age for Windows (version 16.0, SPSSInc., Chicago, Illinois).
P ≤ 0.05 was considered as statistically significant.
Results
The study comprised 180 individuals (44.4 % boys) with
mean ± SD age of 14.32 ± 2.6 years. The median of adi-
ponectin concentrations was 2.95 μg/ml (interquartile
range 2.72–3.30) and 4.55 μg/ml (interquartile range
3.02–5.75) in those with and without Mets, respectively.
Table 1 presents the anthropometric and cardiometa-
bolic characteristics of the participants. Fifteen percent
of girls and 21.2 % of boys had Mets. Other than SBP
and DBP, the mean ± SD of cardiometabolic factors was
higher in those with Mets than those without the Mets.
Participants with Mets had also significantly lower
serum levels of adiponectin (P < 0.001).
The correlation between adiponectin concentrations
and metabolic parameters are shown in Table 2. A signifi-
cant negative correlation existed between adiponectin and
BMI, waist circumference (WC), abdominal obesity, TG,
total cholesterol, and relatively strong correlation with
FBG (r = −0.72, P < 0.001), LDL-C (r = −0.55, P < 0.001),
and HDL-C (r = +0.65, P < 0.001).
Moreover, significant correlations were observed among
both genders regarding HDL-C, FBG, LDL-C, and total
cholesterol. Adiponectin significantly associated with BMI
and WC in boys, but not in girls.
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As depicted in Fig. 1, a decreasing trend was observed
in adiponectin concentrations according to the number
of abnormal metabolic factors from 0–1–2, and to ≥3 in
both boys and girls (P for trend <0.001).
Logistic regression models investigating the association
between adiponectin and Mets are presented in Table 3. A
significant inverse associationwas documented between
adiponectin levels and the presence of Mets (OR, 0.21;
95%CI: 0.09–0.45; p < 0.001). This association remained
significant after adjusting for other risk factors. In an addi-
tive multivariate model, after adjustment for age, BMI,
total cholesterol and WC, this association remained sig-
nificant between adiponectin and Mets in boys (OR, 0.14;
95%CI: 0.03–0.68; P = 0.01) and in girls (OR, 0.15; 95%CI:
0.03–0.64; P = 0.01).
Discussion
The current study documented an inverse and inde-
pendent association of adiponectin with cardiometabolic
factors in adolescent girls and boys. Our findings are in
line with previous studies that had shown a significant
association between lower adiponectin concentrations
with the risk of Mets development in healthy and type 2
diabetic adults [17, 18].
A previous study among adults reported [19] a negative
association between adiponectin and BMI, WC, FBG and
TG. It was also positively associated with HDL-C. Adipo-
nectin has insulin- sensitizing effects through increasing
5’–AMP-activated protein kinase (AMPK) activation in
the peripheral tissues [20]. These effects stimulate fatty
acid oxidation in muscle cells and suppress glucose pro-
duction in liver [21]. Therefore, adiponectin is one of the
insulin- sensitizing hormones strongly associated with in-
sulin resistance- related disorders including Mets [22].
Moreover, our findings on the association of adiponectin
with lipid profile are in accordance with a growing body
of literature suggesting that adiponectin has a direct ef-
fect on the regulation of lipid metabolism through its
effect on lipoprotein lipase activity [23, 24]. Two inde-
pendent studies showed that circulating adiponectin
concentrations are negatively correlated with TG and
positively correlated with HDL-C [24, 25]. Therefore, it
might be of particular importance to consider adipo-
nectin levels in primary prevention of atherosclerotic
events associated with Mets [22].
Although we did not document any significant relation
of adiponectin levels with SBP and DBP, several studies
Table 1 Baseline anthropometric and metabolic parameters of
studied groups
Mets – (n = 148) Mets + (n = 32) P - value
Age (Yr) 14.19 ± 2.64 14.91 ± 2.32 0.16
Weight (Kg) 42.41 ± 16.53 55.06 ± 17.81 <0.001
Height (Cm) 151.07 ± 14.46 156.94 ± 11.49 0.03
BMI (Kg/m2) 17.93 ± 4.28 21.85 ± 4.86 <0.001
WC (cm) 64.51 ± 9.20 75.50 ± 13.71 <0.001
Waist- to -height ratio 0.43 ± 0.04 0.48 ± 0.07 <0.001
SBP (mmHg) 99.68 ± 12.87 105.23 ± 19.49 0.07
DBP (mmHg) 63.91 ± 9.83 64.54 ± 11.62 0.77
FPG (mg/dL) 93.47 ± 9.69 108.75 ± 5.51 0.16
TG (mg/dL) 91.61 ± 37.26 143.10 ± 65.26 <0.001
HDL-C (mg/dL) 66.53 ± 20.78 44.06 ± 13.78 <0.001
LDL-C (mg/dL) 71.39 ± 32.37 96.90 ± 26.17 <0.001
Total Cholesterol (mg/dL) 148.20 ± 37.54 170.75 ± 26.58 0.002
Adiponectin (μg/ml)a 4.55(3.02–5.75) 2.95(2.75–3.30) <0.001
Values are presented as mean ± standard deviation
aValue is median with interquartile rung
Mets metabolic syndrome, BMI body mass index, WC waist circumference, SBP
systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density
lipoprotein cholesterol, TG triglycerides, FBG fasting blood glucose, LDL-C low
density lipoprotein cholesterol
Table 2 Spearman correlation of adiponectin levels with cardiometabolic parameters
Boys Girls Total
r P value r P value r P value
BMI (kg/m2) −0.32 0.004 −0.12 0.24 −0.21 0.004
WC (cm) −0.23 0.04 −0.16 0.12 −0.19 0.009
Abdominal obesity −0.13 0.27 −0.25 0.01 −0.18 0.02
SBP (mmHg) −0.03 0.82 −0.15 0.15 −0.10 0.20
DBP (mmHg) −0.11 0.34 −0.15 0.15 −0.05 0.54
HDL-C (mg/dl) +0.67 <0.001 +0.64 <0.001 +0.65 <0.001
TG (mg/dl) −0.19 0.10 −0.13 0.18 −0.15 0.05
FBG (mg/dl) −0.73 <0.001 −0.71 <0.001 −0.72 <0.001
LDL-C (mg/dl) −0.52 <0.001 −0.58 <0.001 −0.55 <0.001
Total cholesterol (mg/dl) −0.37 0.001 −0.30 0.002 −0.32 <0.001
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, TG triglycerides,
FBG fasting blood glucose, LDL-C low density lipoprotein cholesterol
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in adult populations reported inverse correlation of adi-
ponectin with hypertension in healthy or diabetic indi-
viduals [26, 27].
Our finding on the inverse association of adiponectin
with WC and abdominal obesity is consistent with
some previous studies among adults [28]. It seems that
the influence of adiponectin concentrations in intra-
abdominal fat mass is greater than its influence on sub-
cutaneous fat. As suggested by a previous experimental
study, adiponectin administration induces weight loss,
such effect has been independent of reducing the food
intake in mice fed with high- fat diet [22]. The signifi-
cant inverse association of adiponectin level with WC,
BMI, and abdominal obesity in our study might be ex-
plained by the independent effect of adiponectin on
weight loss [22].
We further investigated the adiponectin- Mets associ-
ation by controlling it for other cardiometabolic parame-
ters, as confounding factors. On all models, adiponectin
increased the risk of Mets independent of age, BMI,
WC, and total cholesterol. Our results support the find-
ings of other studies that have analyzed the relationship
between adiponectin concentrations and Mets [29, 30].
This association might be the effect ofadiponectinon
Mets components. Adiponectin promotes to decrease
TG levels, increasing glucose uptake by skeletal muscle
and increasing HDL-C by an effect on hepatic lipase
activity [31].
Ethnic differences are major factors in determining the
expression level of adiponectin and its association with
metabolic disorders as Mets [32, 33]. Various genetic
backgrounds in different ethnicity may reflect on the
relation between adiponectin and various cardiometa-
bolic risk factors [34, 35]. The available data regarding
the adiponectin concentrations in an Iranian adolescent
population are scarce. Therefore, this study represents
an important landmark in relating to adiponectin with
Mets in Iran.
Fig. 1 Adiponectin concentrations according to the number of metabolic syndrome components in girls and boys
Table 3 Association of serum adiponectin concentrations with metabolic syndrome in Iranian adolescents
Boys Girls Total
OR (95%CI) P- value OR (95%CI) P- value OR (95%CI) P- value
Model 1 0.19(0.06–0.59) 0.004 0.18(0.05–0.64) 0.008 0.21(0.10–0.45) <0.001
Model 2 0.19(0.06–0.61) 0.005 0.16(0.05–0.59) 0.006 0.20(0.09–0.43) <0.001
Model 3 0.15(0.04–0.66) 0.012 0.16(0.04–0.64) 0.009 0.19(0.08–0.46) <0.001
Model 4 0.15(0.03–0.68) 0.014 0.18(0.05–0.72) 0.015 0.21(0.08–0.51) 0.001
Model 5 0.14(0.03–0.68) 0.014 0.15(0.03–0.64) 0.01 0.18(0.07–0.47) <0.001
OR odds ratio, CI confidence interval
Model 1: crude model
Model 2: adjustment for age
Model 3: adjustment for age, body mass index (BMI)
Model 4: adjustment for age, BMI, total cholesterol
Model 5: adjustment for age, BMI, total cholesterol and waist circumference
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The present study has a number of limitations. It was
cross-sectional and we could not explore a causal rela-
tion between adiponectin concentrations and develop-
ment of Mets in adolescents. Another limitation of our
study is that we did not consider dietary factors which
may play important roles in the association adiponectin
and Mets. The strengths of our study are its novelty in
the Middle Eastern population and studying the adoles-
cent age group.
Conclusion
The study highlights the inverse and independent asso-
ciation ofadiponectin with the presence of Mets in
Iranian adolescents. The major finding of our study was
thatadiponectinexhibited a significantly higher prob-
ability of having Mets and was independent of BMI and
other factors. Some physicians may have problems with
including another criterion for the definition of the
metabolic syndrome. In conclusion, we suggest that
adiponectin would be a useful marker for identification
the Mets.
These findings can be used in comparison with other
ethnic groups. Further longitudinal studies are necessary
to assess the clinical impact of such inverse association.
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